Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection?

André J Scheen^{1

2}

Affiliations

¹ Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.
² Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège, Belgium.

Editorial

André J Scheen. Ann Transl Med. 2018 Nov.

. 2018 Nov;6(Suppl 1):S68.

doi: 10.21037/atm.2018.10.39.

André J Scheen^{1

2}

¹ Division of Clinical Pharmacology, Centre for Interdisciplinary Research on Medicines (CIRM), University of Liège, Liège, Belgium.
² Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, Liège, Belgium.

No abstract available

Conflict of interest statement

Conflicts of Interest: The author has no conflicts of interest to declare.

Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
Kuchay MS, Krishan S, Mishra SK, Farooqui KJ, Singh MK, Wasir JS, Bansal B, Kaur P, Jevalikar G, Gill HK, Choudhary NS, Mithal A. Kuchay MS, et al. Diabetes Care. 2018 Aug;41(8):1801-1808. doi: 10.2337/dc18-0165. Epub 2018 Jun 12. Diabetes Care. 2018. PMID: 29895557 Clinical Trial.

1. Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab 2002;16:703-16. 10.1053/beem.2002.0225 - DOI - PubMed
1. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388-402. 10.1016/j.jhep.2015.11.004 - DOI - PubMed
1. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2018. [Epub ahead of print]. 10.1016/S2213-8587(18)30154-2 - DOI - PubMed
1. Younossi Z, Tacke F, Arrese M, et al. Global perspectives on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Hepatology 2018. [Epub ahead of print]. - PubMed
1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-64. 10.1016/j.jhep.2014.12.012 - DOI - PubMed